China approves first CAR-T therapy for solid tumours
Chinese regulators have approved what the South China Morning Post describes as the first CAR-T cell therapy for solid tumours. The treatment was developed by a Shanghai-based drug company, and a New Zealander with advanced stomach and small-intestine cancer became its first international recipient.
Chinese regulators approved the world’s first CAR-T cell therapy for solid tumour cancers in June, the South China Morning Post reports. The treatment was developed by a drug company based in Shanghai. About a month after the approval, a hospital in the city administered it to a New Zealander with advanced cancer of the stomach and small intestine.
The patient was described as the first international recipient of the treatment. The report identifies the therapy as chimeric antigen receptor T-cell treatment, a form of cancer therapy that had previously been approved only for blood cancers. The development extends the use of CAR-T therapy to solid tumours, according to the report.
The supplied material does not identify the company, provide clinical results or describe the patient’s response to treatment, so it does not establish how effective or widely available the therapy will be.
This independently written report is based on information supplied by the named publisher. Vertrix News has not independently verified the source report.